Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Vera Therapeutics stock | $17.09

Learn how to easily invest in Vera Therapeutics stock.

Vera Therapeutics Inc is a biotechnology business based in the US. Vera Therapeutics shares (VERA) are listed on the NASDAQ and all prices are listed in US Dollars. Vera Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Vera Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VERA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vera Therapeutics stock price (NASDAQ: VERA)

Use our graph to track the performance of VERA stocks over time.

Vera Therapeutics shares at a glance

Information last updated 2021-10-18.
Latest market close$17.09
52-week range$11.30 - $33.45
50-day moving average $19.20
200-day moving average $17.01
Wall St. target price$26.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-19.17

Buy Vera Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vera Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vera Therapeutics price performance over time

Historical closes compared with the close of $17.09 from 2021-10-22

1 week (2021-10-15) 13.86%
1 month (2021-09-24) 1.73%
3 months (2021-07-23) -2.90%
6 months (2021-04-20) N/A
1 year (2020-10-20) N/A
2 years (2019-10-20) N/A
3 years (2018-10-20) N/A
5 years (2016-10-20) N/A

Vera Therapeutics financials

Gross profit TTM $0
Return on assets TTM -100.23%
Return on equity TTM -198.65%
Profit margin 0%
Book value $4.33
Market capitalisation $319.4 million

TTM: trailing 12 months

Shorting Vera Therapeutics shares

There are currently 111,089 Vera Therapeutics shares held short by investors – that's known as Vera Therapeutics's "short interest". This figure is 377.9% up from 23,247 last month.

There are a few different ways that this level of interest in shorting Vera Therapeutics shares can be evaluated.

Vera Therapeutics's "short interest ratio" (SIR)

Vera Therapeutics's "short interest ratio" (SIR) is the quantity of Vera Therapeutics shares currently shorted divided by the average quantity of Vera Therapeutics shares traded daily (recently around 150120.27027027). Vera Therapeutics's SIR currently stands at 0.74. In other words for every 100,000 Vera Therapeutics shares traded daily on the market, roughly 740 shares are currently held short.

To gain some more context, you can compare Vera Therapeutics's short interest ratio against those of similar companies.

However Vera Therapeutics's short interest can also be evaluated against the total number of Vera Therapeutics shares, or, against the total number of tradable Vera Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vera Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Vera Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0197% of the tradable shares (for every 100,000 tradable Vera Therapeutics shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vera Therapeutics.

Find out more about how you can short Vera Therapeutics stock.

Vera Therapeutics share dividends

We're not expecting Vera Therapeutics to pay a dividend over the next 12 months.

Vera Therapeutics overview

Vera Therapeutics, Inc. , a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc.

Frequently asked questions

What percentage of Vera Therapeutics is owned by insiders or institutions?
Currently 0.949% of Vera Therapeutics shares are held by insiders and 80.639% by institutions.
How many people work for Vera Therapeutics?
Latest data suggests 13 work at Vera Therapeutics.
When does the fiscal year end for Vera Therapeutics?
Vera Therapeutics's fiscal year ends in December.
Where is Vera Therapeutics based?
Vera Therapeutics's address is: 170 Harbor Way, South San Francisco, CA, United States, 94080
What is Vera Therapeutics's ISIN number?
Vera Therapeutics's international securities identification number is: US92337R1014
What is Vera Therapeutics's CUSIP number?
Vera Therapeutics's Committee on Uniform Securities Identification Procedures number is: 923351100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site